Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation discusses Kevin's accurate information on hair loss treatments and highlights Dr. Bloxham's ongoing work with Verteporfin on FUT scars, suggesting people follow Dr. Bloxham's YouTube for updates. It also thanks Haicafe and Melvin from the hair restoration network forum for their contributions.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

The conversation discusses the importance of scalp skin barrier health in hair follicle cycling, suggesting treatments like ceramides or niacinamide to support hair growth. It also mentions the use of finasteride for hair loss.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

The user started using finasteride, minoxidil, and biotin for male pattern baldness (MPB) and is experiencing rapid thinning. They are questioning if low blood flow to the head could be contributing to their hair loss.

A husband experiencing hair loss is considering treatments like topical minoxidil and finasteride but is concerned about their effects on his pregnant wife and future child. Alternatives suggested include oral finasteride, which is considered safe if hands are washed after use, and exploring natural methods like oils.

You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.

Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The post and conversation are about a user who made their own Platelet-Rich Plasma (PRP) for hair loss treatment at home, using their own blood and a centrifuge. The responses vary, with some users supporting the DIY approach to save money, others expressing concern about the safety and effectiveness of the method, and a few joking about the lengths people will go to combat hair loss.

The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.